Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 11,400 shares of Opko Health stock on the open market in a transaction that occurred on Friday, August 15th. The stock was purchased at an average price of $9.09 per share, with a total value of $103,626.00. Following the transaction, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $18,292,507. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Opko Health (NYSE:OPK) opened at 9.06 on Wednesday. Opko Health has a 1-year low of $7.32 and a 1-year high of $12.95. The stock’s 50-day moving average is $8.92 and its 200-day moving average is $8.82. The company’s market cap is $3.889 billion.

Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter last year, the company posted ($0.01) earnings per share. Opko Health’s revenue was down 1.3% compared to the same quarter last year. On average, analysts predict that Opko Health will post $-0.33 earnings per share for the current fiscal year.

A number of research firms have recently commented on OPK. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Opko Health has an average rating of “Buy” and a consensus target price of $12.00.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.